200 related articles for article (PubMed ID: 1907433)
1. [The potentials of combined chemotherapy in disseminated ovarian cancer].
Gorbunova VA; Perevodchikova NI; Kozachenko VP; Ryzhakov VM; Marenich AF; Zhordania KI
Akush Ginekol (Mosk); 1991 Feb; (2):54-7. PubMed ID: 1907433
[No Abstract] [Full Text] [Related]
2. Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
Sessa C; Colombo N; Bolis G; Marsoni S; Mangioni C
Cancer Treat Rev; 1991 Mar; 18 Suppl A():37-46. PubMed ID: 1904308
[No Abstract] [Full Text] [Related]
3. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
4. [Comparative research on different treatment regimens in disseminated cancer of the ovaries].
Marinov L; Koĭnov K; Tsekova V; Velikova M
Akush Ginekol (Sofiia); 1987; 26(1):49-52. PubMed ID: 3592111
[No Abstract] [Full Text] [Related]
5. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
6. Use of cis-platinum in the treatment of ovarian carcinoma. Clinical results and evaluation of nephrotoxicity.
Giannattasio M; Rizzi R; Coratelli P; Restaino A; Selvaggi L; Ferreri R; Orlando E; Ierardi GM; Granata A; Bettocchi S
Eur J Gynaecol Oncol; 1983; 4(1):41-3. PubMed ID: 6407837
[No Abstract] [Full Text] [Related]
7. Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
Carlson JA; Day TG; Botts B; Masterson BJ
Gynecol Oncol; 1985 Oct; 22(2):189-94. PubMed ID: 3932141
[TBL] [Abstract][Full Text] [Related]
8. [Chemotherapy in advanced forms of carcinoma of the ovary].
Calciati A; Clerico M; Donadio M; Giaccone G
Minerva Ginecol; 1984 Apr; 36(4):195-8. PubMed ID: 6431334
[No Abstract] [Full Text] [Related]
9. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
[No Abstract] [Full Text] [Related]
10. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
van der Hoop RG; van der Burg ME; ten Bokkel Huinink WW; van Houwelingen C; Neijt JP
Cancer; 1990 Oct; 66(8):1697-702. PubMed ID: 2119878
[TBL] [Abstract][Full Text] [Related]
11. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
Greco FA; Johnson DH; Hainsworth JD
Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.
Piver MS; Lele S; Barlow JJ
Cancer Treat Rep; 1981; 65(1-2):149-51. PubMed ID: 6784921
[TBL] [Abstract][Full Text] [Related]
13. [Combined chemotherapy including platinum derivatives in the combined treatment of patients with stage-III to -IV ovarian cancer].
Perevodchikova NI; Gorbunova VA; Grigorova TM; Kozachenko VP; Marenich AF
Vestn Akad Med Nauk SSSR; 1986; (5):8-11. PubMed ID: 3755271
[No Abstract] [Full Text] [Related]
14. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer.
Bruckner HW; Cohen CJ; Goldberg JD; Kabakow B; Wallach RC; Deppe G; Reisman AZ; Gusberg SB; Holland JF
Am J Obstet Gynecol; 1983 Mar; 145(6):653-8. PubMed ID: 6402934
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of drug-resistant ovarian cancer: a Southwest Oncology Group Study.
Laufman LR; Green JB; Alberts DS; O'Toole R; Hilgers RD; Young DC; Lin F; Rivkin SE
J Clin Oncol; 1986 Sep; 4(9):1374-9. PubMed ID: 3091778
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy of epithelial ovarian carcinoma].
Bruntsch U; Gallmeier WM
MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
[No Abstract] [Full Text] [Related]
17. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC
Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer: what is poor prognosis disease?
Cohen MH
J Clin Oncol; 1990 Jul; 8(7):1287-8. PubMed ID: 2113572
[No Abstract] [Full Text] [Related]
19. The case for combination chemotherapy in the treatment of advanced ovarian cancer.
Ozols RF
J Clin Oncol; 1985 Nov; 3(11):1445-7. PubMed ID: 3932603
[No Abstract] [Full Text] [Related]
20. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Heintz AP; van Lent M; Trimbos JB; Bouma J; Vermorken JB
J Clin Oncol; 1987 Aug; 5(8):1157-68. PubMed ID: 3114434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
